Stay updated on Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Sign up to get notified when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.

Latest updates to the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page
- Check5 days agoChange DetectedAdded related topics: Multiple myeloma and MedlinePlus Genetics to the page; no changes to study details or eligibility criteria.SummaryDifference0.1%

- Check12 days agoChange DetectedRemoved the term 'Multiple myeloma' from the page content and deleted the MedlinePlus Genetics related topic.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded related topics: Multiple myeloma and MedlinePlus Genetics; the page revision updated to v3.3.3. Removed the HHS Vulnerability Disclosure link and updated the footer revision from v3.3.2.SummaryDifference0.2%

- Check33 days agoChange DetectedRemoved related topics links for 'Multiple Myeloma' and 'MedlinePlus Genetics' from the page. This affects navigation references but does not modify core trial content.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 in the page footer. No other visible changes to the study details or page layout.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded 'Multiple myeloma' and related topics (MedlinePlus Genetics). Included a note that publications are automatically filled from PubMed and updated the revision tag to v3.3.1.SummaryDifference0.2%

Stay in the know with updates to Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.